GlaxoSmithKline in a Rare-Disease Pact with Prosensa for RNA-modulation Drugs
GSK is paying £16m ($25m) upfront for rights to Prosensa's lead Duchenne's compound, and takes hallmark options to related candidates.
GSK is paying £16m ($25m) upfront for rights to Prosensa's lead Duchenne's compound, and takes hallmark options to related candidates.